Secondary Hyperparathyroidism – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Secondary Hyperparathyroidism – Pipeline Review, H1 2017’, provides an overview of the Secondary Hyperparathyroidism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary Hyperparathyroidism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism

The report reviews pipeline therapeutics for Secondary Hyperparathyroidism by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Secondary Hyperparathyroidism therapeutics and enlists all their major and minor projects

The report assesses Secondary Hyperparathyroidism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Secondary Hyperparathyroidism

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc

Deltanoid Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corp

OPKO Health Inc

Shire Plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Secondary Hyperparathyroidism - Overview

Secondary Hyperparathyroidism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Secondary Hyperparathyroidism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Secondary Hyperparathyroidism - Companies Involved in Therapeutics Development

Amgen Inc

Deltanoid Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corp

OPKO Health Inc

Shire Plc

Secondary Hyperparathyroidism - Drug Profiles

cinacalcet hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTA-091 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTAP-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

evocalcet - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lunacalcipol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Secondary Hyperparathyroidism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS-110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS-411 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Secondary Hyperparathyroidism - Dormant Projects

Secondary Hyperparathyroidism - Discontinued Products

Secondary Hyperparathyroidism - Product Development Milestones

Featured News & Press Releases

Jan 31, 2017: Kyowa Hakko Kirin Announces Top-Line Results of Phase 3 Clinical Study of KHK7580 with Secondary Hyperparathyroidism in Japan

Dec 01, 2015: Kyowa Hakko Kirin Announces Commencement of Phase 3 Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan

Oct 15, 2014: Deltanoid's DP001 (2MD) pharmaceutical demonstrated safe and effective in kidney failure patients on dialysis

Aug 29, 2014: Kyowa Hakko Kirin Announces Commencement of Phase 2b Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan

Jun 27, 2013: Kyowa Hakko Kirin Files Application Seeking Approval For Additional Indication For Regpara Tablets 25mg And 75mg

Mar 07, 2013: Health Canada Cautions Against Use Of Amgen's Sensipar In Children

Feb 26, 2013: Amgen's Pediatric Clinical Trial Of Sensipar Suspended By FDA Following Death Of Patient

Nov 03, 2012: Amgen Announces Results From Phase III EVOLVE Trial Of Sensipar/Mimpara In Patients With Secondary Hyperparathyroidism And Chronic Kidney Disease Receiving Dialysis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Secondary Hyperparathyroidism, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Secondary Hyperparathyroidism – Pipeline by Amgen Inc, H1 2017

Secondary Hyperparathyroidism – Pipeline by Deltanoid Pharmaceuticals Inc, H1 2017

Secondary Hyperparathyroidism – Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Secondary Hyperparathyroidism – Pipeline by OPKO Health Inc, H1 2017

Secondary Hyperparathyroidism – Pipeline by Shire Plc, H1 2017

Secondary Hyperparathyroidism – Dormant Projects, H1 2017

Secondary Hyperparathyroidism – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Secondary Hyperparathyroidism, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports